Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Gregory WM, Prior TJ, Bartlett JB, Sonneveld P, Dimopoulos MA, Moreau P, Usmani S, Facon T. Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. Clin Cancer Res. 2025 Jun 03; 31(11):2154-2161.
-
Sorial MN, Han JX, Koh MJ, Boussi L, Li S, Duan R, Lu J, Lei MM, MacVicar CT, Freydman J, Malespini J, Aniagboso KN, McCabe SM, Peng L, Singh S, Iwasaki M, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Yeterian M, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study. Br J Haematol. 2025 Jun; 206(6):1664-1677.
-
You B, Anderson C, Cecere SC, Carrot A, Myers T, Heitz F, Sharma S, Sel?ukbiricik F, Aghajanian C, Fernebro J, Blank S, Laudani ME, Thaker PH, Yunokawa M, Willmott L, Lisyanskaya A, Hegg R, He Y, Landen C, Lin YG, Alarc?n J, Moore KN. Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial. Gynecol Oncol. 2025 Jun; 197:66-73.
-
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
-
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
-
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol. 2025 May; 114(5):883-889.
-
Bhutani M, Robinson M, Foureau D, Atrash S, Paul B, Guo F, Grayson JM, Ivanina-Foureau A, Pineda-Roman M, Varga C, Friend R, Ferreri CJ, Begic X, Norek S, Drennan T, Anderson MB, Symanowski JT, Voorhees PM, Usmani SZ. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):507-519.
-
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Mart? JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025 Apr; 31(4):1195-1202.
-
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.
-
Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, Kumar S, Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 02; 145(1):75-84.